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Background: The authors of recent studies have reported newly devised implant-speciﬁc blood metal ion thresholds to
predict adverse reactions to metal debris (ARMD) in patients who have undergone unilateral or bilateral metal-on-metal
(MoM) hip arthroplasty. These thresholds were most effective for identifying patients at low risk of ARMD. We investigated
whether these newly devised blood metal ion thresholds could effectively identify patients at risk of ARMD after MoM hip
arthroplasty in an external cohort of patients.
Methods: We performed a validation study involving 803 MoM hip arthroplasties (323 unilateral Birmingham Hip Re-
surfacing [BHR], 93 bilateral BHR, and 294 unilateral Corail-Pinnacle implants) performed in 710 patients at 3 European
centers. All patients underwent whole-bloodmetal ion sampling, and were divided into 2 groups: those with ARMD (leading
to revision or identiﬁed on imaging; n = 75) and those without ARMD (n = 635). Previously devised implant-speciﬁc blood
metal ion thresholds (2.15 mg/L of cobalt for unilateral BHR; 5.5 mg/L for the maximum of either cobalt or chromium for
bilateral BHR; and 3.57 mg/L of cobalt for unilateral Corail-Pinnacle implants) were applied to the validation cohort, and
receiver operating characteristic curve analysis was used to establish the discriminatory characteristics of each
threshold.
Results: The area under the curve, sensitivity, speciﬁcity, and positive and negative predictive values for the ability of
each implant-speciﬁc threshold to distinguish between patients with and without ARMD were, respectively, 89.4% (95%
conﬁdence interval [CI] = 82.8% to 96.0%), 78.9%, 86.7%, 44.1%, and 96.9% for unilateral BHR; 89.2% (CI = 81.3% to
97.1%), 70.6%, 86.8%, 54.5%, and 93.0% for bilateral BHR; and 76.9% (CI = 63.9% to 90.0%), 65.0%, 85.4%, 24.5%,
and 97.1% for unilateral Corail-Pinnacle implants. Using the implant-speciﬁc thresholds, we missed 20 patients with
ARMD (2.8% of the patients in this series). We missed more patients with ARMD when we used the ﬁxed thresholds
proposed by regulatory authorities: 35 (4.9%) when we used the U.K. threshold of 7 mg/L for both cobalt and chromium
continued
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(p = 0.0003), 21 (3.0%) when we used the U.S. threshold of 3mg/L for both cobalt and chromium (p = 1.0), and 46 (6.5%)
when we used the U.S. threshold of 10 mg/L for both cobalt and chromium (p < 0.0001).
Conclusions: This external multicenter validation study conﬁrmed that patients with blood metal ion levels below new
implant-speciﬁc thresholds have a low risk of ARMD after MoM hip arthroplasty. Using these implant-speciﬁc thresholds,
we missed fewer patients with ARMD compared with when the thresholds currently proposed by regulatory authorities
were used. We therefore recommend using implant-speciﬁc blood metal ion thresholds whenmanaging patients who have
undergone MoM hip arthroplasty.
Level of Evidence: Diagnostic Level III. See Instructions for Authors for a complete description of levels of evidence.
L
arge-diameter metal-on-metal (MoM) hip arthroplasties
have had unexpected high failure rates, with many revi-
sions performed for adverse reactions to metal debris
(ARMD)1-4. In an attempt to identify ARMD early, worldwide
regulatory authorities recommend regular patient follow-up5-7,
including measurement of blood cobalt and chromium con-
centrations, which reﬂect in vivo bearing wear8. However, there
is presently no international consensus on the blood metal ion
threshold(s) that should cause clinical concern after a MoM hip
arthroplasty, with previous studies showing that thresholds that
have been used for identifying poorly functioning MoM hip
replacements (3.5 to 7 mg/L) have had insufﬁcient sensitivity9-13.
Two recent studies identiﬁed implant-speciﬁc blood
metal ion thresholds in patients who had undergone unilateral
or bilateral Birmingham Hip Resurfacing (BHR; Smith &
Nephew) or unilateral Corail-Pinnacle total hip replacement
(DePuy)14,15. These designs are 2 of the most commonly im-
planted MoM hip devices worldwide3,16,17. The newly devised
implant-speciﬁc thresholds were most effective for identifying
patients at low risk of ARMD. Application of ﬁxed blood metal
ion thresholds to all patients treated with MoM hip arthro-
plasty has been recommended by the U.K. Medicines and
Healthcare products Regulatory Agency (MHRA) (7 mg/L for
both cobalt and chromium)5 and by experts in the U.S. (3 mg/L
and 10 mg/L for both cobalt and chromium)18. Investigators
who used the new implant-speciﬁc thresholds14,15 missed
fewer patients with ARMD than when they used the ﬁxed
thresholds proposed by regulatory authorities5,18. The im-
plant-speciﬁc thresholds were derived in a large patient cohort
(n = 783) and appear to be useful when managing patients with
these particular MoM implant designs14,15. However, these
implant-speciﬁc thresholds have to be externally validated in
multiple centers before being used clinically19, even though this
type of rigorous approach has not been used in many clinical
prediction studies20.
We investigated whether these newly devised implant-
speciﬁc blood metal ion thresholds could effectively identify
MoM-treated patients at risk of ARMD in an external cohort
of patients with BHR and Corail-Pinnacle implants.
Materials and Methods
An external multicenter validation cohort study was performed in 3 Eu-ropean arthroplasty institutions to investigate the ability of the previously
devised implant-speciﬁc thresholds to discriminate between patients with and
without ARMD
21
. BHRs and/or 36-mm MoM Corail-Pinnacle total hip re-
placements had been implanted at these centers; speciﬁc information about
these implant designs was described previously
14
. Ethical approval was not
required for our study as all centers prospectively followed patients with MoM
implants according to published regulatory guidance
5,7
. The BHR and Corail-
Pinnacle patient cohorts at each center have been previously described, with the
follow-up protocols and blood metal ion analytical methods also detailed
22-26
.
Speciﬁc details related to each center are provided below.
Center 1
Between 1999 and 2009, 646 BHR implants were used
22
. Following arthro-
plasty, all patients underwent clinical assessment, which included a history,
examination, anteroposterior pelvic radiographs, and completion of the Ox-
ford Hip Score (OHS) questionnaire
27
. Patients with hip problems (pain,
swelling, or noises) and/or a suboptimal OHS (£41 of 48 points) underwent
blood metal ion sampling and hip ultrasound examination
4
. Asymptomatic
patients with a BHR also underwent blood sampling and ultrasound if they
were considered to have risk factors for ARMD (a small femoral component, a
malpositioned acetabular component, or radiographic abnormalities including
osteolysis or neck narrowing)
28-32
or if they had concerns about the implant
because of media attention. In addition, 128 asymptomatic patients with a BHR
(OHS > 41 points) underwent blood sampling and ultrasound as part of a
previous study
23
. Metal artifact reduction sequence magnetic resonance imaging
(MARS-MRI) was reserved for equivocal or complex cases
33
.
Center 2
At this center, 425 BHR implants were used
24
between 2001 and 2012 and 17
Corail-Pinnacle implants were used between 2005 and 2010
25
. Following ar-
throplasty, all patients, regardless of symptoms, underwent clinical assessment
including pelvic and hip radiographs and blood metal ion sampling. All symp-
tomatic patients, and asymptomatic patients with blood cobalt and/or
chromium concentrations of ‡5 mg/L, underwent MARS-MRI or, if that was
contraindicated, ultrasound. Selected asymptomatic patients with blood
metal ion concentrations of <5 mg/L also underwent cross-sectional imaging
at the surgeons’ discretion—for example, if there were concerns about the
radiographic appearance or if the contralateral arthroplasty required cross-
sectional imaging.
Center 3
Between 2006 and 2011, 601 Corail-Pinnacle implants were performed
26
. Fol-
lowing arthroplasty, all patients, regardless of symptoms, underwent
clinical assessment including pelvic radiographs and blood metal ion sam-
pling. All symptomatic patients, and asymptomatic patients with blood cobalt and/
or chromium concentrations of >7 mg/L (the MHRA upper limit)
5
, underwent
ultrasound examination. MARS-MRI was reserved for equivocal or complex cases.
Selected asymptomatic patients with blood metal ion concentrations of £7 mg/L
also underwent cross-sectional imaging at the surgeons’ discretion as described
above.
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Inclusion/Exclusion Criteria and Definitions
The same selection criteria (Fig. 1) and deﬁnitions used by the investiga-
tors who derived the blood metal ion thresholds
14,15
were applied to this
validation cohort. For the present study, whole-blood cobalt and chromium
samples obtained up until October 2016 were eligible for inclusion. Patients
with a unilateral arthroplasty had a native contralateral hip at the time of
blood sampling, whereas those who had undergone bilateral arthroplasty
were included in the present study only if both implants were a BHR at the
time of sampling. All blood samples were obtained at least 1 year following
the primary arthroplasty and before any revision surgery. Patients who had
undergone blood sampling before revision for non-ARMD indications had
been excluded from the previous studies
14,15
to reduce the risk of con-
founding factors when thresholds speciﬁc for ARMD were devised. In all
such cases, the intraoperative ﬁndings at the revision and the results of
histopathological and microbiological analyses conﬁrmed the absence of
ARMD.
The patients were divided into ARMD and non-ARMD groups. The
ARMD group included patients who had undergone or were awaiting revision
for ARMD, and those with cross-sectional imaging evidence of ARMD who
were under surveillance because of their own or their clinician’s preference.
Recommendations for revision surgery were always based on the outcome
of the complete clinical assessment and never on the blood metal ion con-
centrations alone
13-15
. A diagnosis of ARMD was made if there was cross-
sectional imaging and intraoperative evidence of a pseudotumor (a cystic, solid,
or mixed mass communicating with the hip joint), or if there was substantial
metallosis, synovitis, tissue damage and/or necrosis in the absence of a pseu-
dotumor
4,30,32-35
. In patients undergoing revision, the diagnosis of ARMD
was conﬁrmed if there was also histopathological evidence of lymphocytic
Fig. 1
Study inclusion and exclusion criteria. ARMD =
adverse reactions to metal debris, BHR = Bir-
minghamHipResurfacing, andCP=Corail-Pinnacle.
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inﬁltrates (including aseptic lymphocytic vasculitis and associated lesions) and
a phagocytic macrophage response to metal wear debris, with or without tissue
necrosis
36-38
.
The non-ARMD group included all patients who did not undergo
a revision for ARMD or who did not demonstrate cross-sectional imaging
evidence of ARMD, regardless of symptoms
14,15
. Patients with bilateral BHRs
who had ARMD in 1 or both hips were considered to have ARMD; otherwise,
the patient was placed in the non-ARMD group. If patients had undergone
multiple blood tests, the most recent result was used if the patient was in the
non-ARMD group, with the result immediately prior to the revision used if the
patient was in the ARMD group. For patients with evidence of ARMD on cross-
sectional imaging, the most recent result was used.
Statistical Analysis
Baseline differences between the patients in the ARMD group and those in the
non-ARMD group were assessed using either the chi-square test (for sex) or 2-
sided unpaired t tests (for age, femoral head size, and time to the blood test).
Unpaired t tests were also used to compare the logarithms of the 3 blood metal
ion parameters (cobalt, chromium, and the maximum value of either cobalt
or chromium) between the ARMD and non-ARMD groups.
The use of receiver operating characteristic (ROC) curve analysis for
assessing the ability of blood metal ion testing to identify patients with ARMD
has been described
14,15
. Previously devised implant-speciﬁc blood metal ion
thresholds (2.15mg/L of cobalt for unilateral BHR, 5.5mg/L for the maximum
of either cobalt or chromium for bilateral BHR, and 3.57 mg/L of cobalt for
unilateral Corail-Pinnacle implants)
14,15
were applied to the validation cohort,
with ROC curve analysis used to establish the discriminatory characteristics of the
3 respective thresholds for identifying patients with ARMD. The area under the
curve (AUC), sensitivity, speciﬁcity, positive predictive value (PPV), negative
predictive value (NPV), and positive and negative likelihood ratios were calcu-
lated with their respective 95% conﬁdence intervals (CIs) for each implant
(unilateral BHR, bilateral BHR, unilateral Corail-Pinnacle).
Fixed thresholds proposed by regulatory authorities in the U.K. (7mg/L)
5
and U.S. (3 mg/L and 10 mg/L)
18
were applied to the validation cohort and
compared, using the McNemar test, with the implant-speciﬁc thresholds
14,15
in terms of the number of patients with ARMDwho were not detected. A p value
of <0.05 was considered signiﬁcant for all analyses.
Results
The validation cohort included 710 patients with a total of803 MoM hip arthroplasties (Table I and Fig. 1), of which
75 (11%) were in the ARMD group and 635 (89%) were in the
non-ARMD group. All blood metal ion parameters were sig-
niﬁcantly higher in the ARMD group than in the non-ARMD
group (p < 0.001; Table II).
Validation of Implant-Specific Blood Metal Ion
Thresholds (Table III)
Unilateral BHR cohort (n = 323): The AUC in the validation
cohort was 89.4% (CI = 82.8% to 96.0%), compared with
90.5% (CI = 82.8% to 98.1%) in the derivation cohort14. The
implant-speciﬁc unilateral BHR threshold (2.15mg/L of cobalt)
had a sensitivity (percentage of patients with ARMD who had
a cobalt concentration above the threshold), speciﬁcity (per-
centage of patients without ARMD who had a cobalt concen-
tration below the threshold), PPV (percentage of patients with
a cobalt concentration above the threshold who had ARMD),
and NPV (percentage of patients with a cobalt concentration
below the threshold who did not have ARMD) of 78.9%,
86.7%, 44.1%, and 96.9%, respectively, for distinguishing
TABLE I Patient Demographics (N = 803 Metal-on-Metal Hips in 710 Patients)*
Parameter All Patients ARMD Group Non-ARMD Group
P Value: ARMD
Versus Non-ARMD
Unilateral BHR
No. (%) of patients 323 (100) 38 (12) 285 (88)
Sex (F/M) 117/206 27/11 90/195 <0.0001‡
Age at blood test† (yr) 63.0 (32.5-84.4) 59.8 (34.3-77.5) 63.4 (32.5-84.4) 0.0673
Time between op. and blood test† (yr) 9.1 (1.9-15.2 )
Femoral head size† (mm) 50.5 (38-58) 47.2 (38-58) 50.9 (38-58) 0.0001‡
Bilateral BHR
No. (%) of patients 93 (100) 17 (18) 76 (82)
Sex (F/M) 33/60 12/5 21/55 0.0022‡
Age at blood test† (yr) 63.5 (36.5-82.6) 59.3 (49.4-70.4) 64.4 (36.5-82.6) 0.0069‡
Time between op. and blood test† (yr) 8.2 (1.2-14.3 )
Femoral head size† (mm) 50.7 (42-58) 48.4 (42-54) 51.0 (42-58) 0.0088‡
Unilateral Corail-Pinnacle
No. (%) of patients 294 (100) 20 (7) 274 (93)
Sex (F/M) 210/84 12/8 198/76 0.3599
Age at blood test† (yr) 78.7 (52.1-95.4) 74.0 (54.6-87.8) 79.1 (52.1-95.4) 0.0143‡
Time between op. and blood test† (yr) 3.6 (1.1-8.4 )
*ARMD =adverse reactions tometal debris, BHR=BirminghamHipResurfacing, F = female, andM=male.†The values are given as the mean with
the range in parentheses. ‡A signiﬁcant difference.
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between patients with and without ARMD after unilateral
BHR in the validation cohort.
Bilateral BHR cohort (n = 93): The AUC in the validation
cohort was 89.2% (CI = 81.3% to 97.1%) compared with
91.0% (CI = 84.5% to 97.4%) in the derivation cohort15. Use of
the implant-speciﬁc threshold for bilateral BHR (maximum
value of either cobalt or chromium of 5.5 mg/L) resulted in a
sensitivity, speciﬁcity, PPV, and NPVof 70.6%, 86.8%, 54.5%,
and 93.0%, respectively, for distinguishing between patients
with and without ARMD after bilateral BHR in the validation
cohort.
Unilateral Corail-Pinnacle cohort (n = 294): The AUC in
the validation cohort was 76.9% (CI = 63.9% to 90.0%)
compared with 79.6% (CI = 68.8% to 90.4%) in the deriva-
tion cohort14. The implant-speciﬁc threshold for the unilat-
eral Corail-Pinnacle implants (3.57 mg/L of cobalt) had a
sensitivity, speciﬁcity, PPV, and NPVof 65.0%, 85.4%, 24.5%,
and 97.1%, respectively, for distinguishing between patients
*ARMD = adverse reactions to metal debris, AUC = area under the curve, BHR = BirminghamHip Resurfacing, NPV = negative predictive value, and
PPV = positive predictive value. †The 95% CI is given in parentheses.
TABLE III Results of Receiver Operator Characteristic Analysis* 
Blood Metal Ion Threshold (mg/L) AUC† (%) Sensitivity† (%) Speciﬁcity† (%)
Unilateral BHR (n = 323) 2.15 (cobalt) 89.4 (82.8-96.0) 78.9 (66.0-91.9) 86.7 (82.7-90.6)
Bilateral BHR (n = 93) 5.5 (maximum of cobalt or
chromium)
89.2 (81.3-97.1) 70.6 (48.9-92.2) 86.8 (79.2-94.4)
Unilateral Corail-Pinnacle (n = 294) 3.57 (cobalt) 76.9 (63.9-90.0) 65.0 (44.1-85.9) 85.4 (81.2-89.6)
TABLE II Blood Metal Ion Concentrations*
Parameter All Patients ARMD Group Non-ARMD Group
P Value: ARMD
Versus Non-ARMD
Unilateral BHR
No. (%) of patients 323 (100) 38 (12) 285 (88)
Implant-speciﬁc threshold (mg/L) 2.15 (cobalt)
Concentration† (mg/L)
Cobalt 1.40 (1.00-1.95) 9.75 (2.35-31.1) 1.30 (1.00-1.70) <0.0001‡
Chromium 1.29 (0.90-2.40) 8.92 (3.50-33.4) 1.18 (0.80-1.80) <0.0001‡
Maximum of cobalt or chromium 1.50 (1.10-2.55) 10.5 (4.16-44.9) 1.40 (1.00-2.00) <0.0001‡
Bilateral BHR
No. (%) of patients 93 (100%) 17 (18%) 76 (82%)
Implant-speciﬁc threshold (mg/L) 5.5 (maximum of cobalt
or chromium)
Concentration† (mg/L)
Cobalt 2.10 (1.50-3.30) 6.30 (4.80-22.5) 1.80 (1.30-2.52) 0.0002‡
Chromium 2.30 (1.40-5.10) 8.50 (5.20-24.1) 2.04 (1.30-2.90) 0.0002‡
Maximum of cobalt or chromium 2.50 (1.70-5.10) 8.50 (5.36-24.1) 2.30 (1.60-2.92) 0.0001‡
Unilateral Corail-Pinnacle
No. (%) of patients 294 (100%) 20 (7%) 274 (93%)
Implant-speciﬁc threshold (mg/L) 3.57 (cobalt)
Concentration† (mg/L)
Cobalt 1.12 (0.65-2.75) 4.66 (1.50-8.07) 1.06 (0.65-2.46) 0.0008‡
Chromium 1.09 (0.83-1.77) 2.47 (1.75-4.16) 1.07 (0.78-1.66) <0.0001‡
Maximum of cobalt or chromium 1.36 (0.88-2.87) 4.66 (2.17-8.07) 1.30 (0.88-2.49) <0.0001‡
*ARMD = adverse reactions to metal debris, and BHR = Birmingham Hip Resurfacing. †The values are given as the median with the interquartile
range in parentheses. ‡A signiﬁcant difference.
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with and without ARMD after unilateral Corail-Pinnacle
implants in the validation cohort.
Implant-Specific Thresholds Versus Fixed Thresholds
Proposed by Regulatory Authorities
Using implant-speciﬁc thresholds, we missed 20 patients with
ARMD (2.8% of the patients in our validation cohort). Signiﬁ-
cantly more patients with ARMDwere missed when we used the
ﬁxed threshold of 7 mg/L (4.9%, n = 35; p = 0.0003) or 10 mg/L
(6.5%, n = 46; p < 0.0001). Use of the ﬁxed threshold of 3 mg/L
resulted in 1 more patient with ARMD being missed (3.0%, n =
21) thanwhenwe used the implant-speciﬁc thresholds; however,
this difference was not signiﬁcant (p = 1.0).
Discussion
Although blood metal ion levels are commonly measuredduring patient follow-up, there is presently no international
consensus regarding the appropriate threshold(s) for clinical con-
cern5-7,18,39. The authors of 2 recent studies reported the novel ob-
servation of implant-speciﬁc bloodmetal ion thresholds in patients
treated with unilateral or bilateral BHR or unilateral Corail-
Pinnacle implants14,15. These thresholds were effective for identify-
ing patients at low risk of ARMD, with fewer patients with ARMD
being missed than when the ﬁxed thresholds proposed by regula-
tory authorities were used5,18. We have now validated the ﬁndings
from these derivation studies14,15 in our large multicenter study.
The validation study was large—its size was similar to that
of the derivation cohort—and it was truly external as it included
patients from 3 geographically different centers40,41. Very similar
ﬁndings were observed when the implant-speciﬁc thresholds
for unilateral BHR, bilateral BHR, and unilateral Corail-
Pinnacle implants14,15 were applied to the validation cohort,
with the 3 thresholds demonstrating a good ability to dis-
tinguish between patients with and without ARMD (a high
AUC) with good and balanced sensitivity and speciﬁcity.
Furthermore, the implant-speciﬁc thresholds were effective
for identifying hips without ARMD (a high NPV). These
characteristics were generally better in the BHR validation
cohorts than in the Corail-Pinnacle validation cohort, which
parallels the ﬁndings in the derivation studies14,15. Although
the implant-speciﬁc thresholds performed marginally better
overall in the derivation cohort14,15 than in the validation
cohort, this is to be expected. Statistical models invariably
perform better in the derivation cohort than in external
cohorts because they are intimately related to the patient,
surgical, and unmeasured factors from the derivation study,
which can never be reproducible externally42,43. However, the
degree to which our ﬁndings in the validation cohort parallel
those in the derivation studies is reassuring.
Using the implant-speciﬁc thresholds in our validation co-
hort, we missed signiﬁcantly fewer patients with ARMD than we
missed when using the ﬁxed threshold of 7 mg/L proposed by the
U.K.MHRA5 or the ﬁxed U.S. threshold of 10mg/L18; in fact, use of
the 10 mg/L threshold more than doubled the number of patients
with ARMD who were missed. When we applied the lower U.S.
threshold (3 mg/L) to the validation cohort we missed 1 more
patient with ARMD than when we used the implant-speciﬁc
thresholds, but this difference was not statistically signiﬁcant.
However, as previously discussed14,15, such a difference is considered
clinically relevant given the destructive potential of ARMD and
poor outcomes reported following MoM hip revision surgery44.
It is recommended that similar implant-speciﬁc blood
metal ion thresholds be developed for other commonly used
MoM hip arthroplasty designs, as such thresholds may also
perform better than the ﬁxed thresholds currently recommended
by regulatory authorities5,18. Although their methodology and
selection criteria differed from those in the derivation studies14,15,
Hart et al. observed that 7 mg/L was the “optimal” threshold for
predicting failure of the recalled Articular Surface Replacement
(ASR; DePuy) hip resurfacing and ASR XL total hip arthro-
plasty13. This ﬁnding provides further support for the belief that,
similar to MoM hip arthroplasty revision rates3,16, clinically im-
portant blood metal ion thresholds are implant-speciﬁc. Authors
of future studies should ensure that they apply the same metho-
dology as described here and previously14,15, which includes fo-
cusing on ARMD-related failures (including those not treated with
revision but identiﬁed on imaging), as we consider these methods
largely responsible for the better diagnostic performance
observed with the implant-speciﬁc thresholds compared with
the blood metal ion thresholds from previous studies9,12,13.
The management of patients after MoM hip arthroplasty
is complex39. As observed in this cohort (Table I) and previ-
ously4,17,28, there are recognized risk factors for developing
ARMD such as female sex, young age at arthroplasty, and a
PPV† (%) NPV† (%) Misclassiﬁcation (%)
No. of Patients with
ARMD Missed
Likelihood Ratio†
Positive Negative
44.1 (32.3-55.9) 96.9 (94.7-99.0) 14.2 8 5.92 (4.22-8.31) 0.24 (0.13-0.45)
54.5 (33.7-75.4) 93.0 (87.0-98.9) 16.1 5 5.37 (2.78-10.32) 0.34 (0.16-0.71)
24.5 (12.9-36.1) 97.1 (95.0-99.2) 16.0 7 4.45 (2.90-6.85) 0.41 (0.23-0.75)
TABLE III (continued)
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small resurfacing femoral head. These factors are useful for
risk-stratifying patients for surveillance18,39. It is important to
recognize that no single investigation should be used alone in the
clinical decision-making process for patients who have under-
gone MoM hip arthroplasty18. Therefore, blood metal ion levels
should be only a part of the complete clinical assessment.
Although ﬁxed thresholds proposed by worldwide reg-
ulatory authorities are widely used5,18, it is worth considering
how they were formulated. In 2010, theMHRA ﬁrst proposed 7
mg/L as the blood metal ion threshold for clinical concern,
which was considered reasonable at the time given that ARMD
was a new entity 5. However, the MHRA still recommends that
clinicians use the 7 mg/L threshold5 despite multiple studies
suggesting evidence to the contrary, with lower thresholds
being preferred9-12,14,15. The more recent consensus statement
from experts in the U.S. represents an attempt to risk-stratify
patients with MoM implants to assist in management, which is
commendable18. However, the 3 mg/L and 10 mg/L thresholds
that they recommended appear to have been arbitrarily selected
rather than supported by clinical data18. In contrast, the im-
plant-speciﬁc thresholds have now been assessed in nearly
1,500 patients with MoM hip implants from 4 different Eu-
ropean centers14,15. Implant-speciﬁc thresholds were con-
sistently shown, in both the derivation studies5,18 and our
validation cohort, to be effective for identifying patients at low
risk of ARMD after BHR or Corail-Pinnacle implants, and we
missed fewer patients with ARMD than we missed when we
used ﬁxed thresholds proposed by regulatory authorities. Al-
though the prevalence of ARMD varies among different insti-
tutions because of differences in surveillance methods and
thresholds for revision45, this validation study has demon-
strated that implant-speciﬁc blood metal ion thresholds
perform well in different centers. We therefore consider our
evidence-based implant-speciﬁc thresholds to be useful for
managing patients after BHR and Corail-Pinnacle implants.
This study has limitations. In center 1, not all asymp-
tomatic patients underwent blood metal ion sampling. This se-
lection bias existed in the derivation cohorts14,15 and may affect
the generalizability of implant-speciﬁc thresholds. However,
universal blood sampling was performed at the other 2 validation
centers, suggesting that implant-speciﬁc thresholds are effective
in centers using either universal or targeted blood sampling.
Another selection bias at all centers was the use of targeted cross-
sectional imaging for asymptomatic patients with increased
blood metal ion levels. Although this reﬂects the approach used
in the clinical setting, where follow-up resources must be ratio-
nalized5-7,12,14,15,17, it is possible that some asymptomatic patients
had silent ARMD but were incorrectly assigned to the non-
ARMD group. The use of targeted imaging for asymptomatic
patients therefore has the potential to affect the discriminatory
characteristics reported in the validation cohort; however, a
previous sensitivity analysis of patients undergoing cross-
sectional imaging produced results similar to those for the
whole cohort15. Although the validation cohort was large and
its size was similar to that of the derivation cohort, the bilateral
BHR group (n = 93) was smaller in the validation study than in
the derivation study (n = 185)15. This may have affected the
discriminatory characteristics in the bilateral BHR validation
group. There were also limitations related to using only a single
blood metal ion reading for each patient in the analysis, and the
inﬂuence of patient and laboratory factors on blood metal ion
levels have been detailed previously14,15. Finally the validated
thresholds apply only to patients with a unilateral or bilateral
BHR implant or a unilateral Corail-Pinnacle implant.
In conclusion, this large external multicenter validation
study conﬁrmed that patients with BHR or Corail-Pinnacle
MoM implants and blood metal ion levels below newly devised
implant-speciﬁc thresholds14,15 were at a low risk of ARMD.
Using these implant-speciﬁc thresholds enabled us to miss
fewer patients with ARMD than when we used current ﬁxed
thresholds proposed by regulatory authorities5,18. We therefore
recommend using implant-speciﬁc blood metal ion thresholds
when managing patients who have undergone MoM hip ar-
throplasty with BHR or Corail-Pinnacle implants. n
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